Sutro Biopharma Inc. (STRO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Sutro Biopharma Inc. (NASDAQ: STRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.10 (-0.44% 1D, market cap $151.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, STRO ranks #641 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), STRO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TARA (Protara Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -34.7%, cap $148.9M) and CRDL (Cardiol Therapeutics Inc. (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M). Among the 5-stock peer group, STRO leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
Per STRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382101), Sutro Biopharma Inc. generated $102.5M in revenue (+65.2% YoY), -$191.0M in net income, and -$177.2M in free cash flow against $173.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 25.2 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While STRO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.39) and Max Pain ($9.56) forces dealer call-delta covering toward $46.04.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sutro Biopharma Inc. (STRO) slipped -0.44% to $9.10, trading at 5% of its 52-week range ($7.15 – $43.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year — — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +65.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on STRO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for STRO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sutro Biopharma Inc. (STRO) ranks #641 by composite RQD confidence (36/100, grade D-) and #609 by equity capitalization ($151.6M). Within this direct 5-issuer industry benchmark cohort, STRO leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. CRDL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with STRO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STRO
ACTIVE
Sutro Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -0.44% | $151.6M | Benchmark Subject |
| TARA Protara Therapeutics Inc. | D- | 43/100 | — | — | -34.7% | -1.59% | $148.9M | /tara-vs-stro → |
| CRDL Cardiol Therapeutics Inc. (Class A) | D+ | 52/100 | — | — | — | -5.13% | $141.2M | /crdl-vs-stro → |
| CHRS Coherus Oncology Inc. | D- | 36/100 | — | — | -35.0% | -7.60% | $138.8M | /chrs-vs-stro → |
| ABOS Acumen Pharmaceuticals Inc. | D- | 38/100 | — | — | -35.0% | -90.82% | $165.6M | /abos-vs-stro → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sutro Biopharma Inc. (STRO) reported GAAP revenue of $102.5M (+65.2% vs. FY2024 revenue of $62.0M , and -33.3% cumulative change since FY2023) , GAAP net income of -$191.0M, operating cash flow of -$177.2M, and free cash flow of -$177.2M (+7.5% YoY). On the balance sheet, STRO closed FY2025 with $173.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $102.5M | -$191.0M | -$177.2M | -$177.2M | $173.8M | — |
| FY2024 (FY) | 2024-12-31 | $62.0M | -$227.0M | -$191.5M | -$191.5M | $387.2M | — |
| FY2023 (FY) | 2023-12-31 | $153.7M | -$107.0M | -$111.6M | -$111.6M | — | — |
As of 2026-11-02, Sutro Biopharma Inc. (NASDAQ: STRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $9.10 (-0.44% 1D, market cap $151.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, STRO ranks #641 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), STRO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TARA (Protara Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -34.7%, cap $148.9M) and CRDL (Cardiol Therapeutics Inc. (Class A)) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $141.2M). Among the 5-stock peer group, STRO leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
Per STRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001382101), Sutro Biopharma Inc. generated $102.5M in revenue (+65.2% YoY), -$191.0M in net income, and -$177.2M in free cash flow against $173.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
STRO last traded at $9.10 (-0.44% on volume of 122,356 shares), positioning the stock -40.87% below its 50-day simple moving average ($15.39) and -60.49% below its 200-day simple moving average ($23.03). Across its 52-week range of $7.15 to $43.85, STRO sits at the 5.3% percentile with a 14-day RSI of 25.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($7.96 to $10.24).
Why STRO Stock slipped -0.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).